As a clinician, understanding the unique challenges pain management patients face is a formidable task. Pain is personal. Only those affected grasp its impact on their daily lives. Studies have shown that impact is significant: chronic pain and pain-related conditions limit quality of life. That’s one of the many reasons why Belmar Pharma began compounding low-dose naltrexone.
Naltrexone has been historically prescribed at doses around 50 mg to treat different forms of addiction. Low-dose naltrexone or LDN, compounded at significantly lower doses, has demonstrated a wide range of benefits across multiple disease states. As an anti-inflammatory, it has the potential to relieve painful symptoms associated with chronic illness. As an immune-modulator, LDN may encourage improved immune system performance, benefiting those with autoimmune disease. Additionally, LDN can behave synergistically when combined with other pain therapies, creating a multifaceted method to combat illness.
Diminishing pain benefits patients by improving sleep, cognitive function, and state of mind. Many patients experience minimal side effects. While sleep disturbances and headaches are possible, they are transient and easily addressed with temporary dose deductions.
Available in multiple dosage forms, LDN can be formulated to aid patients with allergies or sensitivities that may have restricted past medical options. Our team of pharmacists will guide your practice through dosing titrations geared specifically for the individual patient.
If you are a clinician interested in prescribing compound medications to your patients, contact us for information on how to get started and to access all our clinical resources.
